SHTG Daily Digest — Weiss Lab

A quiet week for new mechanistic and trial data, but two notable items: the 2026 ACC/AHA dyslipidemia guideline drops in Circulation (now formally folding hypertriglyceridemia into the same document as cholesterol), and three independent correspondence letters in NEJM probe the olezarsen pancreatitis-risk findings reported earlier this year by the TIMI group.

A thin original-research week, but two genuinely high-impact items: the new joint 2026 ACC/AHA dyslipidemia guideline (which now formally addresses hypertriglyceridemia and Lp(a) alongside LDL-C), and three published letters in NEJM debating the CORE-TIMI 72a/b olezarsen trial — including the Marston/Bergmark/Sabatine reply.

A thin but consequential week — the new 2026 ACC/AHA dyslipidemia guideline lands in *Circulation* and explicitly folds hypertriglyceridemia into the cholesterol-management framework, while *NEJM* publishes a correspondence cluster pressure-testing the pancreatitis-risk findings of the pivotal olezarsen (APOC3) trial.

The week's literature is dominated by meta-analytic syntheses of APOC3-targeting agents (olezarsen and plozasiran) and ANGPTL3 inhibitors, converging on a consistent message — both pathways produce profound TG lowering with acceptable safety profiles, and plozasiran in particular now has the first prospective RCT evidence for reducing recurrent acute pancreatitis in FCS patients.